Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcmg.2017.08.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between the Biomarkers of Collagen Regulation and Echocardiography Parameters in Patients With Heart Failure With Preserved Ejection Fraction.
Kardiologiia
December 2024
Tyumen Cardiological Research Center, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk.
Aim: To study the relationship between laboratory markers and echocardiography (EchoCG) parameters in heart failure with preserved ejection fraction (HFpEF) depending on the results of the diastolic stress test (DST).
Material And Methods: The diagnostic algorithm provided by the current guidelines for the assessment of left ventricular (LV) diastolic function was used to select patients. If there were not enough criteria to make a conclusion about increased LV filling pressure (FP) based on standard resting echocardiography data in patients with arterial hypertension and ischemic heart disease, DST was performed to detect HFpEF.
The association between estimated pulse wave velocity and cardio-cerebrovascular disease risk: a cohort study.
Eur J Med Res
January 2025
Department of Geriatrics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524000, Guangdong, China.
Background: Various measures of arterial stiffness have been linked to the risk of cardiovascular disease. However, the relationship between the estimated pulse wave velocity (ePWV), a novel indicator of arterial stiffness, and cardio-cerebrovascular disease risk remains unclear. This study investigated the relationship between the ePWV and the risk of cardio-cerebrovascular diseases.
View Article and Find Full Text PDFThe N-Terminal Mutations of cMyBP-C Affect Calcium Regulation, Kinetics, and Force of Muscle Contraction.
Int J Mol Sci
December 2024
Institute of Immunology and Physiology, Russian Academy of Sciences, 620049 Yekaterinburg, Russia.
The cardiac myosin binding protein-C (cMyBP-C) regulates cross-bridge formation and controls the duration of systole and diastole at the whole heart level. As known, mutations in cMyBP-C increase the cross-bridge number and rate of their cycling, hypercontractility, and myocardial hypertrophy. We investigated the effects of the mutations D75N and P161S of cMyBP-C related to hypertrophic cardiomyopathy on the mechanism of force generation in isolated slow skeletal muscle fibers.
View Article and Find Full Text PDFNon-Invasive Cardiac and Vascular Monitoring in Systemic Sclerosis: Impact of Therapy on Subclinical Dysfunction.
Medicina (Kaunas)
December 2024
Department of Cardiology and Cardiovascular Surgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
: Systemic sclerosis (SSc) causes myocardial and microvascular impairment, with subclinical dysfunction and eventually permanent cardio-vascular damage. The long-term influence of SSc therapies on subclinical cardiovascular dysfunction is insufficiently investigated. We aimed to assess 2D and 4D cardiac ultrasound parameters of heart function in patients with different forms of SSc versus controls and to determine the evolution of cardiac function and arterial stiffness parameters under therapy.
View Article and Find Full Text PDFDulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.
J Clin Med
December 2024
2nd Department of Internal Medicine Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1 Str., Chaidari, 12462 Athens, Greece.
: The association between diabetic nephropathy and arterial elasticity and endothelial function is well established. In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria. : Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!